Fulcrum Therapeutics Inc reports results for the quarter ended in March - Earnings Summary

Fulcrum Therapeutics

15/05/2023 14:31

* Fulcrum Therapeutics Inc  FULC.OQ  reported a quarterly
adjusted
loss of 41 cents​​ per share for the quarter ended in March. The
mean expectation of eight analysts for the quarter was for a
loss of 46 cents per share.
    * Revenue fell 88.6% to $295.00 thousand from a year ago;
analysts
expected $1.13 million. 
    * Fulcrum Therapeutics Inc's reported EPS for the quarter
was a
loss of 41 cents​.
    * The mean earnings estimate of analysts had risen by
about 7.4%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company. 
    * Fulcrum Therapeutics Inc shares had risen by 14.7% this
quarter and lost 55.1% so far this year.
    * The company reported a quarterly loss of $24.78 million.
    * Wall Street's median 12-month price target for Fulcrum
Therapeutics Inc is $7.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," 4
"hold" and 1 "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data May
15 at 01:31 p.m. UTC. ​All figures in US dollars unless
otherwise stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Mar. 31 2023      -0.46          -0.41          Beat
 Dec. 31 2022      -0.49          -0.50          Missed
 Sep. 30 2022      -0.61          -0.51          Beat
 Jun. 30 2022      -0.66          -0.83          Missed